[The influence of changes in the blood pressure and plasma renin activity on the natriuretic effect of nifedipine]. 1991

O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
Unidad de hipertensión (Departamento de Medicina Interna), Hospital General Virgen del Rocío, Sevilla.

BACKGROUND The possible influence of the variations in blood pressure and the plasma renin activity (PRA) after the administration of nifedipine (NIF) on the natriuretic effect of this calcium antagonist were evaluated. METHODS The differences in the values of sodium excretion and tubular reabsorption were evaluated in 18 patients with essential hypertension with the method of the lithium clearance before and after the administration of a sublingual NIF dose. RESULTS An increase in sodium excretion at the expense of a smaller distal reabsorption was found after NIF administration, without differences in patients with (n = 9) or without (n = 9) increase in PRA after NIF administration. The differences in several parameters when patients were classified depending on whether their mean blood pressure was reduced (n = 8) in more than 10% or not (n = 10) 90 minutes after NIF administration are discussed. CONCLUSIONS Natriuresis induced by nifedipine is due to a diminished distal reabsorption of sodium. This effect is independent of PRA or its changes. On the other hand, the differences found in subgroups with different blood pressure response support the hypothesis that there are two populations of patients with essential hypertension depending on their acute response to calcium antagonists.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
January 1990, International journal of clinical pharmacology research,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
January 1978, Arzneimittel-Forschung,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
December 1978, Clinical science and molecular medicine. Supplement,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
August 1985, Artificial organs,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
April 1978, Scandinavian journal of clinical and laboratory investigation,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
January 1979, Acta medica Scandinavica. Supplementum,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
April 1981, Journal of clinical pharmacology,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
March 1973, Acta medica Scandinavica,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
June 1976, British journal of clinical pharmacology,
O Muñiz Grijalvo, and J Carneado de la Fuente, and J Villar Ortiz, and J Lapetra Peralta, and J Molina Miró
January 1985, European journal of clinical pharmacology,
Copied contents to your clipboard!